https://www.selleckchem.com/pe....ptide/tirzepatide-ly
anticoagulation or antiplatelet therapy. We report diagnostic characteristics, as well as short- and long-term outcomes of CeAD. A high MACE rate was observed within the first 2 weeks of CeAD diagnosis, notably in patients not initiated on anticoagulation or antiplatelet therapy. From both a clinical and research perspective, it is important to determine what constitutes a perceivable change in commonly used outcome measures. We aimed to do so for the Symptom Checklist-90-Revised (SCL-90-R). Patients from a large real-world